Clinical trials: Breast Cancer (Early Breast Cancer)
Cardiovascular Diseases
Early Detection of Imaging-derived Subclinical Cardiac Injuries
Breast cancer (BC) radiotherapy leads to incidental cardiac irradiation, resulting in an increased risk of various major cardiac events (MCEs).
- Trial name
- EMIRA (NCT03575650)
- Testing
- Cardiac imaging modalities
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- University Medical Center Groningen
Chemotherapy-Related Cognitive Impairment, Breast Cancer
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.
- Trial name
- NCT05239663
- Testing
- Ganglioside-Monosialic Acid, 250ml normal saline (NS)
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Depression
Survival TRaining for ENhancing Total Health (STRENGTH)
RATIONALE: A home-based exercise and/or diet program may improve the quality of life of breast cancer patients by preventing an increase in body fat and weight and a loss of lean body tissue.
- Conditions
- Breast Cancer, Depression, Weight Changes
- Trial name
- NCT00068458
- Testing
- Calcium-Rich Diet, Arm 2: Exercise + Calcium-Rich Diet, Exercise + Fruit & Vegetable, Low Fat + Calcium Diet
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
This clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05025059
- Testing
- Discussion, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
- Trial name
- NCT00545688
- Testing
- Herceptin, Docetaxel, Pertuzumab
- Where
- 77 sites in Australia, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Hoffmann-La Roche
Early-stage Breast Cancer
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with potentially curative, operated hormone…
- Trial name
- NCT00309491
- Testing
- Tamoxifen alone, Tamoxifen + Aminoglutethimide
- Volunteers
- 2,021 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Neoplasms
Early Detection of Breast Cancer
The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer.
- Trial name
- NCT06043661
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Datar Cancer Genetics Inc
Adherence, Treatment
Factors Influencing Adherence to Adjuvant Endocrine Therapy
Breast cancer is the most common type of cancer and the leading cause of cancer death in women. Adjuvant endocrine therapy (AET) reduces the risk of disease recurrence and mortality in women with hormone-dependent breast cancer.
- Trial name
- NCT06192446
- Testing
- Survey using a questionnaire.
- Where
- Croatia
- Volunteers
- 1,000 people
- Sponsor
- University of Zagreb
Triple-Negative Breast Neoplasm
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs.
- Trial name
- KEY-MELT (NCT07011823)
- Testing
- Partial breast-irradiation
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
ER+ Breast Cancer, HER2-negative Breast Cancer
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Detection of molecular relapse with circulating tumour DNA analysis can identify which patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy.
- Trial name
- TRAK-ER (NCT04985266)
- Testing
- Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen
- Where
- 49 sites in France, United Kingdom
- Volunteers
- 1,100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006256
- Testing
- paclitaxel, adjuvant therapy, radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
The goal of this clinical trial is to learn if serplulimab is effective in early HR+/HER2- breast cancer. It will also learn about the safety of serplulimab.
- Trial name
- NCT06394661
- Testing
- Serplulimab+NabPE
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Early Detection of Cancer
A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers
The purpose of this study is to determine the clinical performance of AI-based Thermalytix with the current standard-of-care diagnostic modalities in women.
- Trial name
- NCT04688086
- Testing
- Thermalytix
- Where
- India
- Volunteers
- 687 people, healthy volunteers welcome
- Sponsor
- Niramai Health Analytix Private Limited
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
This phase II trial studies how well hypofractionated partial breast irradiation works in treating patients with early stage breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT03077841
- Testing
- Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
- Where
- 15 sites in United States
- Volunteers
- 928 people
- Sponsor
- M.D. Anderson Cancer Center
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Cancer Female
Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer
Breast cancer (BC) radiotherapy leads to coincidental radiation of the heart, resulting in increased risk of a variety of heart diseases.
- Trial name
- EARLY-HEART (NCT03297346)
- Testing
- Cardiac imaging and circulating biomarkers
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- French Nuclear Safety and Radiation Protection Authority (ASNR)
Neoplasm, Colorectal, Neoplasm, Breast
Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs
Background: Sweden has a long tradition of organized national population-based screening programs. Participation rates differ between programs and regions, are relatively high in some groups, but lower in other.
- Conditions
- Neoplasm, Colorectal, Neoplasm, Breast, Neoplasm, Ovarian
- Trial name
- BESTa (NCT05512260)
- Testing
- Individual decision aid (iDA)
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Karolinska Institutet
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Relief of Joint Pain
Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms
Significant Aromatase Inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment.
- Trial name
- NCT03069313
- Testing
- Vitamin B12
- Volunteers
- 41 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Breast Cancer Female
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
The study investigates, whether the patient group with intermediate-risk early breast cancer benefits from treatment with ribociclib in combination with endocrine therapy compared to standard-of-care chemotherapy (followed by…
- Trial name
- ADAPTcycle (NCT04055493)
- Testing
- Ribociclib 200Mg Oral Tablet
- Where
- 86 sites in Germany
- Volunteers
- 1,684 people
- Sponsor
- Women's Cancer Study Group GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.